- Filings
- Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
- Profile
-
Financials
Takeda Pharmaceutical Company Limited (TAK) Financial statements
Company Profile
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | ||
|---|---|---|---|---|---|---|---|---|
| Total Revenue | ||||||||
| Cost of Revenue | ||||||||
| Gross Profit | ||||||||
| Gross Profit Margin (%) | ||||||||
| R&D Expense | ||||||||
| SG&A Expense | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income or Loss | ||||||||
| Operating Margin (%) | ||||||||
| Interest Expense | ||||||||
| Total Other Income/Expenses | ||||||||
| Income Before Tax | ||||||||
| Income Tax Expense | ||||||||
| Income from Continuing Ops. | ||||||||
| Net Income | ||||||||
| Net Profit Margin (%) | ||||||||
| Net Income Available to Common Shareholders | ||||||||
| Basic EPS | ||||||||
| Diluted EPS | ||||||||
| Basic Average Shares | ||||||||
| Diluted Average Shares |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | ||
|---|---|---|---|---|---|---|---|---|
| Total Revenue | ||||||||
| Cost of Revenue | ||||||||
| Gross Profit | ||||||||
| Gross Profit Margin (%) | ||||||||
| R&D Expense | ||||||||
| SG&A Expense | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income or Loss | ||||||||
| Operating Margin (%) | ||||||||
| Interest Expense | ||||||||
| Total Other Income/Expenses | ||||||||
| Income Before Tax | ||||||||
| Income Tax Expense | ||||||||
| Income from Continuing Ops. | ||||||||
| Net Income | ||||||||
| Net Profit Margin (%) | ||||||||
| Net Income Available to Common Shareholders | ||||||||
| Basic EPS | ||||||||
| Diluted EPS | ||||||||
| Basic Average Shares | ||||||||
| Diluted Average Shares |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | ||
|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||
| Cash & Cash Equivalents | ||||||||
| Marketable Securities | ||||||||
| Receivables | ||||||||
| Inventories | ||||||||
| Other Current Assets | ||||||||
| Total Current Assets | ||||||||
| Non-Current Assets | ||||||||
| Marketable Securities | ||||||||
| PPE Net | ||||||||
| Intangibles inc. Goodwill | ||||||||
| Other Non-Current Assets | ||||||||
| Total Non-Current Assets | ||||||||
| Total Assets | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | ||||||||
| Deferred Revenues | ||||||||
| Debt, Current | ||||||||
| Accrued Liabilities | ||||||||
| Other Current Liabilities | ||||||||
| Total Current Liabilities | ||||||||
| Non-Current Liabilities | ||||||||
| Deferred Revenues | ||||||||
| Debt, Non-Current | ||||||||
| Other Non-Current Liabilities | ||||||||
| Total Non-Current Liabilities | ||||||||
| Total Liabilities | ||||||||
| Shareholders' Equity | ||||||||
| Common Stock | ||||||||
| Additional Paid-In Capital | ||||||||
| Retained Earnings | ||||||||
| Other Shareholders' Equity | ||||||||
| Total Shareholders' Equity | ||||||||
| Total Liabilities & Shareholders' Equity |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | ||
|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||
| Cash & Cash Equivalents | ||||||||
| Marketable Securities | ||||||||
| Receivables | ||||||||
| Inventories | ||||||||
| Other Current Assets | ||||||||
| Total Current Assets | ||||||||
| Non-Current Assets | ||||||||
| Marketable Securities | ||||||||
| PPE Net | ||||||||
| Intangibles inc. Goodwill | ||||||||
| Other Non-Current Assets | ||||||||
| Total Non-Current Assets | ||||||||
| Total Assets | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | ||||||||
| Deferred Revenues | ||||||||
| Debt, Current | ||||||||
| Accrued Liabilities | ||||||||
| Other Current Liabilities | ||||||||
| Total Current Liabilities | ||||||||
| Non-Current Liabilities | ||||||||
| Deferred Revenues | ||||||||
| Debt, Non-Current | ||||||||
| Other Non-Current Liabilities | ||||||||
| Total Non-Current Liabilities | ||||||||
| Total Liabilities | ||||||||
| Shareholders' Equity | ||||||||
| Common Stock | ||||||||
| Additional Paid-In Capital | ||||||||
| Retained Earnings | ||||||||
| Other Shareholders' Equity | ||||||||
| Total Shareholders' Equity | ||||||||
| Total Liabilities & Shareholders' Equity |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | ||
|---|---|---|---|---|---|---|---|---|
| Cash Flows from Operating Activities | ||||||||
| Net Income | ||||||||
| Depreciation & Amortization | ||||||||
| Deferred Income Taxes | ||||||||
| Stock Based Compensation | ||||||||
| Accounts Receivable | ||||||||
| Inventory | ||||||||
| Accounts Payable | ||||||||
| Deferred Revenue | ||||||||
| Other Non-Cash | ||||||||
| Operating Cash Flow | ||||||||
| Cash Flows from Investing Activities | ||||||||
| PPE Investments | ||||||||
| Net Acquisitions | ||||||||
| Purchase of Investments | ||||||||
| Sale of Investments | ||||||||
| Other Investing Activity | ||||||||
| Investing Cash Flow | ||||||||
| Cash Flows from Financing Activities | ||||||||
| Debt Issued | ||||||||
| Proceeds from Debt Repayment | ||||||||
| Debt Repayment | ||||||||
| Proceeds from Sale of Equity | ||||||||
| Equity Repurchased | ||||||||
| Dividend Paid | ||||||||
| Other Financing Activity | ||||||||
| Financing Cash Flow | ||||||||
| Cash Position | ||||||||
| Beginning Cash Position | ||||||||
| End Cash Position | ||||||||
| Change in Cash | ||||||||
| Free Cash Flow | ||||||||
| Operating Cash Flow | ||||||||
| Capital Expenditure | ||||||||
| Free Cash Flow |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | ||
|---|---|---|---|---|---|---|---|---|
| Cash Flows from Operating Activities | ||||||||
| Net Income | ||||||||
| Depreciation & Amortization | ||||||||
| Deferred Income Taxes | ||||||||
| Stock Based Compensation | ||||||||
| Accounts Receivable | ||||||||
| Inventory | ||||||||
| Accounts Payable | ||||||||
| Deferred Revenue | ||||||||
| Other Non-Cash | ||||||||
| Operating Cash Flow | ||||||||
| Cash Flows from Investing Activities | ||||||||
| PPE Investments | ||||||||
| Net Acquisitions | ||||||||
| Purchase of Investments | ||||||||
| Sale of Investments | ||||||||
| Other Investing Activity | ||||||||
| Investing Cash Flow | ||||||||
| Cash Flows from Financing Activities | ||||||||
| Debt Issued | ||||||||
| Proceeds from Debt Repayment | ||||||||
| Debt Repayment | ||||||||
| Proceeds from Sale of Equity | ||||||||
| Equity Repurchased | ||||||||
| Dividend Paid | ||||||||
| Other Financing Activity | ||||||||
| Financing Cash Flow | ||||||||
| Cash Position | ||||||||
| Beginning Cash Position | ||||||||
| End Cash Position | ||||||||
| Change in Cash | ||||||||
| Free Cash Flow | ||||||||
| Operating Cash Flow | ||||||||
| Capital Expenditure | ||||||||
| Free Cash Flow |